Longevity & AgingAI-Designed Lung Fibrosis Pill Enters Phase III Trial With 320 Patients
Insilico Medicine has launched a Phase III clinical trial of Rentosertib, an oral once-daily pill targeting TNIK, a protein implicated in idiopathic pulmonary fibrosis (IPF). IPF is a fatal lung-scarring disease with limited treatment options. The trial will enroll 320 patients across 47 centers in China over 52 weeks, measuring lung function decline as the primary endpoint. Notably, Rentosertib was discovered entirely using Insilico's AI drug-discovery platform, making it a landmark test of whether AI-generated medicines can succeed in late-stage human trials. Earlier Phase IIa data showed patients on the 60 mg dose gained an average of 98.4 mL in forced vital capacity at 12 weeks — a meaningful signal in a disease where lung function typically deteriorates steadily.
